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Abstract
Direct delivery of cytokines using nanocarriers holds great promise for cancer therapy. However, 
the nanometric scale of the vehicles made them susceptible to size-dependent endocytosis, 
reducing the plasma membrane-associated apoptosis signalling. Herein, we report a tumor 
microenvironment-responsive and transformable nanocarrier for cell membrane targeted delivery 
of cytokine. This formulation is comprised of a phospholipase A2 (PLA2) degradable liposome as 
a shell, and complementary DNA nanostructures (designated as nanoclews) decorated with 
cytokines as the cores. Utilizing the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) as a model cytokine, we demonstrate that the TRAIL loaded DNA nanoclews are capable 
of transforming into nanofibers after PLA2 activation. The nanofibers with micro-scaled lengths 
efficiently present the loaded TRAIL to death receptors on the cancer cell membrane and 
amplified the apoptotic signalling with reduced TRAIL internalization.
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1. Introduction
Delivering protein based anticancer therapeutics[1-4], such as enzymes [5-7], transcription 
factors [8-10], or cytokines [11-13], are gaining increasing interest due to their specific 
activities in inducing apoptosis in cancer cells, reducing normal cell damage than traditional 
chemotherapeutics [14, 15]. When compared with delivering nucleic acid based anticancer 
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gene therapies, directly administering protein formulations would enable better control of 
the dosages as well as ruling out the chance of accidental genetic alterations [16]. While 
reaching intracellular compartments is a prerequisite for many anticancer proteins, like the 
caspase-3 that transmits apoptosis signal in the cytosol [17], or apoptin that takes effect in 
the nucleus [18]; blocking the endocytosis of proteins that target specific receptors on the 
plasma membrane would enhance their signaling, such as the tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), a cytokine that interacts with death receptors on the 
plasma membrane and induces tumor specific apoptosis [19, 20]. However, current 
anticancer protein delivery systems were mostly designed for intracellular delivery by 
harnessing the size-dependent endocytosis of nanoparticles [21-23]; strategies for targeted 
delivery of nanocarriers to plasma membranes while avoiding size-dependent endocytosis 
remain elusive.
Here, we describe a novel rolling circle amplification (RCA) based strategy for cancer cell 
membrane targeted delivery of cytokine in a tumor-microenvironment responsive manner 
[20, 24-26], where the secreted phospholipase A2 (PLA2), an enzyme overexpressed by 
various tumors, including colon, breast, prostate, and gastric cancers [27], was harnessed as 
a spatial-temporal trigger for drug release. Compared with conventional DNA structure 
preparation techniques that require sophisticated DNA oligo design and assembly [28-33], 
rolling circle amplification (RCA) is a facile DNA synthesis technique capable of preparing 
DNA structures spanning the spatial range from nano- [34-38] to micro- [39, 40] and to 
macroscopic scale [41-43]. One amazing property of DNA is that folded DNA 
nanostructures are readily internalized by many types of cancer cell lines [44-47], while free 
DNA chains are impermeable to cell membranes [48]. In our previous reports, we prepared 
self-assembled DNA nanoclews (NCs) by RCA for nuclei targeted delivery of Doxorubicin 
as a tumor microenvironment-triggered anticancer therapy [34] or the CRISPR-Cas9 system 
for targeted genome editing [16]. However, these compact nanocarriers were tailored for 
intracellular targets. To achieve plasma membrane-targeted cytokine delivery, as shown in 
Fig. 1, nanoparticles with a core-shell structure were designed consisting of two functional 
components: 1) a liposome shell that could be specifically degraded by PLA2 and 2) two 
DNA NCs encoding complementary sequences as the cores. For convenient designation, one 
of the complementary DNA NCs was defined as encoding DNA sequence in the forward 
direction (NCf), while the other was defined as encoding sequence in the reverse direction 
(NCr). The model cytokine TRAIL was loaded onto the Ni2+ modified DNA NC cores via 
Ni2+-polyhistidine affinity. We hypothesized that the elevated PLA2 level in the tumor 
microenvironment would promote degradation of the liposome shell, releasing the TRAIL 
loaded DNA NCs into extracellular environment. In cases when only one of TRAIL-NCf-L 
or TRAIL-NCr-L was administered, rapid internalization of the TRAIL loaded DNA NC 
would happen, diminishing the apoptosis signaling induction. However, when both TRAIL-
NCf-L and TRAIL-NCr-L were co-administered, hybridization of the complementary DNA 
NCs could occur extracellularly, transforming the compact DNA nanoparticles into micro-
scaled DNA structures that could serve as multivalent scaffolds for presenting TRAIL to 
death receptors on plasma membrane and reduce its endocytosis to enhance the anticancer 
efficacy.
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2. Materials and Methods
2.1. Materials
All chemicals unless otherwise specified were purchased from Sigma-Aldrich and were used 
as received. DNA oligos were ordered from Integrated DNA Technologies Inc. (Coralville, 
IA, USA). Bst 2.0 DNA polymerase was purchased from New England BioLabs Inc. 
(Ipswich, MA, USA). CircLigase II single-stranded DNA (ssDNA) Ligase was purchased 
from Epicenter (Madison, WI, USA). Aminoallyl-dUTP and Traut's reagent were purchased 
from ThermoFihser Scientific, Inc. (Pittsburgh, PA, USA). Maleimido-C3-NTA was 
purchased from Dojindo Molecular Technologies Inc. (Kumamoto, Japan).
2.2. Preparation of TRAIL
Recombinant TRAIL was expressed and purified as described previously [49]. Briefly, 
Escherichia coli harboring the plasmid pET23dw-His-ILZ-hTRAIL that encodes His-ILZ-
TRAIL (residues 114-281) was cultured in LB medium until the OD600 reached 0.6-0.8. 0.5 
mM isopropylthio-β-galactoside (IPTG) was added to induce TRAIL expression at 20 °C for 
12 h. The cells were then collected by centrifugation and resuspended in buffer A (20 mM 
Tris-HCl, pH 8.0, 20 mM imidazole). After lysis by sonication and centrifugation at 
20,000×g for 20 min, the supernatant of cell lysate was applied to a column containing 
NTA-Ni2+ resin. Followed by washing the column with buffer B (20 mM Tris-HCl, pH 8.0, 
60 mM imidazole), TRAIL was eluted by buffer C (20 mM Tris-HCl, pH 8.0, 500 mM 
imidazole) and dialyzed against PBS at 4 °C overnight. The purified TRAIL was quantified 
by Bradford assay and analyzed by SDS-PAGE.
2.3. Preparation of Ni2+ modified DNA NC
Two complementary DNA NCs modified with NH2 were prepared by RCA [34] with further 
modifications to obtain Ni2+ modified DNA NCs. The ssDNA templates with 5’ 
phosphorylation (Table 1) were cyclized by CircLigase II following manufacturer's 
instructions and uncyclized ssDNA chains were removed with Exonuclease I (NEB). NCs 
modified with primary amines were then prepared by applying aminoallyl-dUTP as a 
building block in the RCA reaction. Briefly, 10 pmol circular ssDNA templates were 
hybridized with corresponding primers at 95 °C for 5 min in 1 × isothermal amplification 
buffer (NEB) supplemented with 200 μM dUTP and 2 μM aminoallyl-dUTP. After cooling 
the solution to room temperature, Bst 2.0 DNA polymerase (0.2 U/μL) was added and the 
reaction was kept at 60 °C for 17 h. The synthesized NCs were centrifuged at 14,000 × g for 
2 min and dialyzed against buffer D (10 mM phosphate buffer, pH 7.4, 2.5 mM EDTA) in a 
Slide-A-Lyzer dialysis unit (20K MWCO, Thermo Scientific). The primary amines on NCs 
were then conjugated with thiol groups using 5 μM Traut's reagent at room temperature for 1 
h and the thiolation was confirmed by thiol detection kit (Cayman) with an efficiency over 
95%. 20 μM maleimido-C3-NTA was then added to conjugate NTA to the thiol groups at 
room temperature for 3 h.[50] After chelating the NTA with 50 μM NiCl2, the Ni2+ modified 
DNA NCs were dialyzed against deionized water for 2-3 days. Concentrations of the 
prepared DNA NCs were determined using Nanodrop 2000C spectrometer (Thermo 
Scientific). Zeta potential and particle size were analyzed by Zetasizer (Nano ZS, Malvern). 
Transmission electron microscopy (TEM) images of the NCs were acquired on a JEOL 
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2000FX microscope at 200 kV with the samples prepared on a TEM copper grid (300 mesh) 
(Ted Pella) and stained by phosphotungstic acid (1%, v:v). Elemental mapping of the DNA 
NCs were performed on an FEI Titan 80-300 aberration corrected STEM with SuperX 
energy dispersive X-ray spectroscopy (EDS) system.
2.4. Characterization of DNA NCs loaded with TRAIL
The His-tagged TRAIL protein was loaded onto Ni2+ modified DNA NCs (1:40, w:w) via 
the affinity between the His-tag and Ni2+ with an excess of Ni2+. The TRAIL loaded NCs, 
TRAIL-NCf and TRAIL-NCr, were then visualized by confocal laser scanning microscope 
(CLSM) with TRAIL labeled by Alexa Fluor 647 (AF 647) and NCs stained with Hoechst 
33342. To obtain TEM image of TRAIL loaded DNA NC, TRAIL was pre-stained with 
mono-sulfo-N-hydroxy-succinimido gold nanoparticle in PBS for 1 h and excessive gold 
nanoparticle (AuNP) was removed by Seperdex-75 gel filtration. Silver enhancement was 
applied for better TEM imaging. For atomic force microscope (AFM) imaging, the NCf and 
NCr were dropped, dried on the silicon wafer and imaged by tapping mode in ambient air 
using a Nanoscope AFM (Veeco, Santa Barbara, CA). Particle size and zeta potential of 
TRAIL loaded NCs were characterized by Zetasizer (Nano ZS, Malvern).
2.5. Encapsulation of DNA NC into liposome and PLA2 triggered release
The TRAIL loaded DNA NCs were encapsulated into 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) liposome by reverse phase evaporation. Briefly, POPC dissolved in 
chloroform (1 mg/mL) and water solution containing TRAIL-NC were mixed (3:1, v:v). A 
nano-emulsion was obtained after sonication and the emulsion was shortly evaporated by a 
rotary vacuum evaporator (Heidolph). Supplemented with another 1 volume of deionized 
water, the emulsion was evaporated again to remove excess chloroform from the solution. 
Unencapsulated TRAIL-NC was removed by dialysis against deionized water in a 1000 KDa 
dialysis unit (Spectrum) after DNase treatment. Particle size and zeta potential of liposome 
were characterized by Zetasizer (Nano ZS, Malvern). POPC liposome was lysed with Triton 
X-100 aqueous solution (1%, v:v) for rapid release of its content. For phospholipase 
mediated release, 15 U/mL of PLA2 from Naja mossambica mossambica (Sigma Aldrich) 
was incubated with the liposome at room temperature for 10 min [51, 52]. The release of 
TRAIL-NC from the POPC liposome was analyzed by 0.8% agarose gel electrophoresis 
with GelRed supplemented as DNA stain and band fluorescence intensity was estimated 
with Image J. The POPC liposome were also characterized by TEM imaging.
2.6. Cell culture
The human colorectal cancer cell line COLO 205 was cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10 % FBS (v:v), 100 U/mL penicillin and 100 
μg/mL streptomycin in a 37 °C incubator (Thermal Scientific) under an atmosphere of 5% 
CO2 and 90% humidity. The cells were sub-cultured regularly with a split ratio of 1:3 and 
the cell densities were quantified using a hemocytometer before each experiment.
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2.7. Cellular distribution and endocytosis pathway of delivered TRAIL
Subcellular localization of delivered TRAIL was monitored using CLSM. COLO 205 cells 
were seeded in confocal microscopy dishes (MatTek) at the density of 1 × 105 cells/well and 
cultured for 48 h. The cells were then incubated with different formulations containing 50 
ng/mL of AF 647 labeled TRAIL at 37 °C for 1 h. After washing the cells with ice-cold PBS 
twice, the cell membranes were stained with 5 μg/mL Alexa Fluor 488 conjugated Wheat 
Germ Agglutinin (WGA) at 37 °C for 10 min. The stained cells were then washed with ice-
cold PBS again and observed with CLSM immediately. For quantitative analysis of 
membrane-bound TRAIL, COLO 205 cells were seeded in 6-well plates (1 × 105 cells/well) 
and cultured for 48 h. The cells were treated with different formulations containing 50 
ng/mL of AF 647 labeled TRAIL for 1 h at 37 °C or 4 °C. Afterwards, the cells were 
collected and analyzed by flow cytometry (Cytoflex, Beckman Coulter) to quantify the total 
TRAIL contents of the cells, including membrane bound and internalized, by measuring the 
mean fluorescence intensities of the cells. Samples treated at 37 °C represent the total 
amount the both membrane-bound and internalized TRAIL while the those treated at 4 °C 
were referred only as TRAIL bound to the cell membrane due the inhibition of endocytosis 
at 4 °C [49]. The uptake pathway of delivered TRAIL (stained with AF 647) was also 
analyzed. COLO 205 cells in the 6-well plates were pre-incubated with different inhibitors 
for endocytosis pathways for 1h at 37 °C [chlorpromazine (CPZ, 10 μM) for clathrin-
mediated endocytosis; methyl-β-cyclodextrin (MCD, 3 mM) for lipid raft; nystatin (NYS, 25 
μg/mL) for cavelolin-mediated endocytosis; and amiloride (AMI, 1 mM) for 
macropinocytosis]. Then the cells were incubated with PLA2 pretreated TRAIL-NCf-L or 
TRAIL-NCr-L in the presence of the inhibitors for another 2h. Mean fluorescence intensities 
of the cells were analyzed by flow cytometry.
2.8. Cell apoptosis assay
The apoptosis inducing capability of TRAIL delivered by different formulations were 
evaluated with the APO-BrdU based terminal deoxynucleotidyl transferase (TdT) dUTP 
Nick-End Labeling (TUNEL) assay kit (Life Technologies) and the Annexin V-FITC 
Apoptosis Detection Kit (BD Bioscences). COLO 205 cells were seeded in 6-well plates and 
cultured for 48 h. The cells were incubated with different formulations containing 20 ng/mL 
of TRAIL for 12 h. Afterwards, the cells were stained following the protocol of the 
manufacturers. For the TUNEL assay, the cells were imaged by fluorescence microscope 
(IX71, Olympus), while for the Annexin V-FITC Apoptosis assay, the cells were analyzed 
by flow cytometry (Cytoflex, Beckman Coulter).
2.9. In vitro cytotoxicity
COLO 205 cells were seeded in 96 well plates at the density of 1 × 104 cells/well and 
cultured for 24 h. To evaluate the anticancer efficacy of TRAIL delivered by the NCs, the 
cells were incubated with TRAIL containing formulations at different TRAIL concentrations 
for 24 h. To evaluate the biocompatibility of the carrier, nanocarriers without TRAIL were 
incubated with the cells at the same concentrations used for TRAIL delivery for 24 h. MTT 
solutions were then added to the cells (final concentration of 0.5 mg/mL) and incubated for 4 
h. After removing the medium, the cells were dissolved with 150 μL DMSO and the 
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absorbances were read on a microplate reader (Infinite M2000 Pro, Tecan) with test 
wavelength of 570 nm and reference wavelength of 630 nm.
2.10. Statistics
All results were calculated as Mean ± SD. Two-tailed student's t-test was performed for 
statistical analysis. The difference between experimental groups and control groups were 
considered statistically significant when P < 0.05 or highly significant when P < 0.01.
3. Results and Discussion
3.1. Preparation and characterization of Ni2+ modified DNA NC
To validate our delivery strategy, we first synthesized the NH2-modified DNA NCs by RCA 
(Fig. 1a). Two ssDNA oligos with complementary sequences were used as templates for the 
RCA (Table 1). Aminoallyl-dUTP was supplemented into the RCA reaction for 
incorporating NH2 groups into the RCA products. After converting NH2 into SH with the 
Traut's reagent, maleimide activated nitrilotriacetic acid (NTA) was conjugated to the DNA 
NC for chelating Ni2+. Both NCf and NCr self-assembled into negatively charged 
nanoparticles (zeta potential of −21 ± 3 mV) with the mean size of 97 nm as determined by 
the TEM, AFM and dynamic light scattering (DLS) (Fig. 2a-c). The Ni2+ modification on 
DNA NC was confirmed by elemental analysis using the EDS mapping on a scanning 
transmission electron microscope (STEM) (Fig. 2d). Next, the morphology of the hybridized 
NCf/NCr was evaluated by TEM and AFM. After incubating at 37 °C for 10 min, the fully 
complementary NCf and NCr merged into micro-scaled fibers (Fig. 2b and c). Due to the 
periodic nature of the DNA strands, strong hybridization of multiple DNA stands generated 
networked fibers with a width of ~ 40 nm and length spanning a few micrometers.
3.2. Loading TRAIL onto DNA NC
TRAIL with a molecular weight of 24 KDa was purified (Fig. 3a) and loaded onto the 
synthesized DNA NCs via the affinity between Ni2+ and the fused His-tag on TRAIL. To 
image the loading of TRAIL onto DNA NC by TEM, TRAIL was labeled with gold 
nanoparticle. Both NCf and NCr were efficient in loading the His-tagged TRAIL, which 
caused negligible changes to the zeta potential (−20 ± 4 mV) and sizes as compared with 
DNA NCs (Fig. 3b). Binding of the TRAIL protein to DNA NCs was also observed by 
CLSM with TRAIL labeled by the infrared AF 647 and NCs stained with Hoechst 33342 
(Fig. 3c). Colocalization of the fluorescence signals further confirmed the binding between 
TRAIL and DNA NCs.
3.3. Encapsulation of TRAIL-NC in POPC liposome and PLA2 triggered release
To prevent the TRAIL loaded DNA NCs from premature hybridization, TRAIL-NCf and 
TRAIL-NCr were encapsulated in liposomes composed of POPC, separately, by the method 
of reverse evaporation [53]. The sn-2 acyl ester bond in POPC can be rapidly degraded by 
the surface active enzyme PLA2 [54], making POPC liposome a PLA2-responsive coating 
for TRAIL delivery. The POPC liposome containing TRAIL-NC showed a mean 
hydrodynamic size of 215 nm (PDI = 0.29 ± 0.03, zeta potential −25 ± 4 mV) (Fig. 4a) and 
the TRAIL-NC was encapsulated with an encapsulation efficiency of 55 % (Fig. 4b). 
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Treating the TRAIL-NC-L with PLA2 for 10 min triggered virtually complete release of the 
encapsulated TRAIL-NC from the liposome (Fig. 4c). When TRAIL-NC-L was treated with 
PLA2, the liposome structure was disrupted and nanoparticles with a size of ~ 100 nm were 
released (Fig. 4d and e). However, microscaled fibers of hybridized TRAIL-NCf/TRAIL-
NCr (1:1 w:w) were observed after PLA2 treatment of the TRAIL-NCf-L/TRAIL-NCr-L 
mix (Fig. 4f), reducing the portion of free nanoparticles.
3.4. Cell membrane targeted delivery of TRAIL
To evaluate the membrane targeted delivery of TRAIL by TRAIL-NCf-L/TRAIL-NCr-L, the 
human colorectal carcinoma cell COLO 205 was chosen as a model cell line due to the 
significantly elevated expression of PLA2 in its tumor extracellular matrix [55]. To 
compensate for the inadequate PLA2 secretion caused by the low cell density in the culture, 
PLA2 pretreatment was applied to release TRAIL-NC from the liposome. Subcellular 
localization of the delivered TRAIL was studied by incubating COLO 205 cells with 
TRAIL-NCf-L or TRAIL-NCr-L separately or simultaneously after PLA2 pretreatment of 
the liposome to mimic the tumor microenvironment. After incubation at 37 °C for 1 h, 
subcellular localization of AF 647 labeled TRAIL was observed by CLSM. As shown in Fig. 
5a, TRAIL delivered by TRAIL-NCf-L or TRAIL-NCr-L separately was mostly internalized 
into the cells. However, the internalization was significantly inhibited when TRAIL-NCf-L 
and TRAIL-NCr-L were co-administered, leaving large part of the administered TRAIL 
bound on cell membrane. Quantitative analysis also confirmed that co-administration of two 
nanoparticles significantly enhanced the percentage of membrane-bound TRAIL to ~ 76% 
from ~42% by separately administered systems (Fig. 5b). Further analysis of the endocytosis 
pathways showed that the TRAIL delivered by TRAIL-NCf-L or TRAIL-NCr-L separately 
was mostly internalized into the COLO 205 cells through clathrin and lipid raft mediated 
pathways (Fig. 5c).
3.5. In vitro cytotoxicity
After confirming the membrane-targeted delivery of TRAIL by TRAIL-NCf-L/TRAIL-NCr-
L, the enhanced apoptosis inducing capability of the co-administrated formulation was then 
evaluated by the TUNEL assay. Cells treated with TRAIL-NCf-L/TRAIL-NCr-L mixture 
after PLA2 pretreatment exhibited higher level of the apoptotic DNA fragmentation as 
observed from the green fluorescence signals compared with those incubated with separated 
formulations (Fig. 6a). The quantitative analysis of the apoptosis was performed using the 
Annexin-FITC staining based flow cytometry. As shown in Fig. 6b, the apoptosis ratios were 
31.7% and 29.6% for PLA2 pretreated TRAIL-NCf-L and TRAIL-NCr-L, respectively; 
while after PLA2 pretreatment, TRAIL-NCf-L/TRAIL-NCr-L co-administration exhibited 
the highest apoptosis inducing capability with an apoptosis ratio of 43.7% after 12 h of 
incubation. The enhanced apoptosis of the co-delivered formulation is consistent with the 
increasing ratio of the membrane bound TRAIL.
The absence of PLA2 pretreatment basically abolished apoptosis inducing capability even 
for the co-administered formulation, indicating that the tumor microenvironment associated 
PLA2 is a required stimulus for TRAIL release. It is worth noting that, TRAIL bound to the 
NCs showed higher apoptotic signaling than free TRAIL, possibly due to the 
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nanovectorization enhanced regional clustering of TRAIL [56]. The in vitro cytotoxicity of 
TRAIL against COLO 205 cells was examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Separately administered TRAIL-NCf-L and 
TRAIL-NCr-L after PLA2 pretreatment showed similar cytotoxicity with a half-maximal 
inhibitory concentration (IC50) of 14 ng/mL, which is significantly lower than that of 
TRAIL-L (IC50 = 24.2 ng/mL) (Fig. 6c). TRAIL delivered by TRAIL-NCf-L and TRAIL-
NCr-L simultaneously after PLA2 pretreatment showed further enhanced cytotoxicity 
towards COLO 205 cells (IC50 = 7.8 ng/mL). Meanwhile, the empty vectors without loaded 
TRAIL did not show any significant cytotoxicity after PLA2 pretreatment (Fig. 6d), 
indicating the biocompatibility of the carriers.
4. Conclusion
In conclusion, we have exploited a novel cancer cell membrane targeted drug delivery 
system using two complementary DNA NCs as a drug loading matrix for regulating protein 
internalization. An enzyme degradable liposome was utilized for spatial-temporal 
hybridization of the DNA NCs. Of note, the morphological transformation of the 
nanoparticles [20, 57] into micro-scaled DNA structures effectively inhibited the endocytosis 
of TRAIL presenting nanoparticle into cancer cells, increasing its anticancer efficacy. This 
strategy provides new guidelines for design of cell membrane targeted drug delivery, which 
can be further expanded to other types of therapeutics.
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Fig. 1. 
Schematic of phospholipase activated membrane targeted cytokine delivery system. (a) 
Preparation of TRAIL-NC-L. The DNA NC was first prepared by RCA and then (I) 
modified with Ni2+. After (II) loading TRAIL through Ni2+-His tag affinity, (III) the 
TRAIL-NC was encapsulated into a POPC liposome that could be degraded by PLA2. (b) 
Main components of TRAIL-NC-L and mechanism of PLA2 triggered morphological 
transformation of the DNA NCs. (IV) Highly expressed PLA2 in the tumor 
microenvironment degrades the liposome shell to release TRAIL-NC. (V) Complementary 
DNA NCs hybridize into microscopic fibers. (c) Effect of the morphological change on 
TRAIL localization. (VI) TRAIL loaded spherical nanoparticle are efficiently internalized. 
(VII) Hybridized DNA fibers are highly impermeable to cell membrane, facilitaing the 
interaction of TRAIL and death receptors.
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Fig. 2. 
(a) Hydrodynamic size distributions and TEM images of the synthesized DNA NCs. scale 
bars 200 nm (b) TEM image of NCf/NCr mix, scale bar 200 nm. (c) AFM imaging of NCf, 
NCr, and NCf/NCr mix. Scale bar represents 500 nm. (d) Representative element mapping 
of Ni2+ modified DNA NC. Shown here is Ni2+ modified NCf, scale bar represents 100 nm.
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Fig. 3. 
(a) SDS-PAGE of purified TRAIL. (b) Hydrodynamic size distributions and TEM imaging 
of TRAIL loaded DNA NCs. TRAIL-NCf and TRAIL-NCr showed similar size distribution 
with a mean diameter of ~104 nm. TRAIL was stained with AuNP. Scale bars represent 100 
nm. (c) CLSM characterization of the colocalization of TRAIL and DNA in TRAIL-NCf 
and TRAIL-NCr. Red fluorescence indicated AF 647 labeled TRAIL; blue fluorescence 
showed Hoechst 33342 stained DNA NCs. Scale bar represents 10 μm.
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Fig. 4. 
(a) Hydrodynamic size distribution of POPC liposome encapsulating TRAIL-NCf. (b) 
Agarose gel electrophoresis analysis of encapsulating DNA NC into POPC liposome. Lane 
L showed DNA ladder, Lane 1: Unpurified TRIAL-NCf-L, Lane 2: Unpurified TRIAL-NCf-
L treated with 1% Triton X-100. Encapsulation efficiency was estimated from the band 
intensity by Image J, where the encapsulated amount is the difference between Lane 2 and 
Lane 1. (c) Release of TRAIL-NC from POPC liposome. Lane L showed DNA ladder; Lane 
1 and 4, purified POPC liposome encapsulating TRAIL-NCf and TRAIL-NCr; Lane 2 and 5, 
TRAIL-NCf-L and TRAIL-NCr-L treated with PLA2; Lane 3 and 6, TRAIL-NCf-L and 
TRAIL-NCr-L treated with 1% Triton X-100 as 100% release. (d) Representative TEM 
image of POPC liposome encapsulating TRAIL-NC. Shown is TRAIL-NCf-L. (e) TEM 
image of TRAIL-NCf-L after PLA2 treatment. (f) TEM image of TRAIL-NCf-L/TRAIL-
NCr-L after PLA2 treatment. Scale bars all indicate 200 nm.
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Fig. 5. 
(a) CLSM analysis of subcellular localization of delivered TRAIL. COLO 205 cells were 
incubated with TRAIL-NCf-L and TRAIL-NCr-L separately or simultaneously after PLA2 
pretreatment. TRAIL was labeled with AF 647 and membrane of COLO 205 cells was 
stained with AF488-WGA. White arrows indicate TRAIL on cell membrane and blue arrows 
indicate internalized TRAIL. Scale bars indicate 20 μm. (b) Quantitative analysis of the 
amount of TRAIL internalized by COLO 205 cells or bound on cell membrane. (c) 
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Endocytosis pathway analysis of TRAIL delivered by TRAIL-NCf-L and TRAIL-NCr-L. 
Data was presented as mean ± SD (n = 3). **P<0.01.
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Fig. 6. 
(a) APO-BrdU TUNEL assay of COLO 205 apoptosis induced by different TRAIL delivery 
formulations after PLA2 pretreatment. Scale bar indicates 200 μm. (b) Annexin V-FITC/PI 
staining based flow cytometry analysis of COLO 205 apoptosis after treating with different 
TRAIL delivery formulations for 12 h. I, control cell untreated with any formulation; II, 
TRAIL-L after PLA2 pretreatment; III, TRAIL-NCf-L after PLA2 pretreatment; IV, TRAIL-
NCr-L after PLA2 pretreatment; V, TRAIL-NCf-L/TRAIL-NCr-L after PLA2 pretreatment; 
VI, TRAIL-NCf-L/TRAIL-NCr-L without PLA2 pretreatment. (c) In vitro cytotoxicity of 
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TRAIL-L, TRAIL-NCf-L, TRAIL-NCr-L and TRAIL-NCf-L/TRAIL-NCr-L after PLA2 
pretreatment. Colo 205 cells were treated with different formulations for 24 h. (d) In vitro 
cytotoxicity of carriers without loaded TRAIL after PLA2 pretreatment. Data were presented 
as mean ± SD (n=6). *P<0.05, **P<0.01.
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